Literature DB >> 11024116

Discordance between bovine leukemia virus tax immortalization in vitro and oncogenicity in vivo.

J C Twizere1, P Kerkhofs, A Burny, D Portetelle, R Kettmann, L Willems.   

Abstract

Bovine leukemia virus (BLV) Tax protein, a transcriptional activator of viral expression, is essential for viral replication in vivo. Tax is believed to be involved in leukemogenesis because of its second function, immortalization of primary cells in vitro. These activities of Tax can be dissociated on the basis of point mutations within specific regions of the protein. For example, mutation of the phosphorylation sites at serines 106 and 293 abrogates immortalization potential in vitro but maintains transcriptional activity. This type of mutant is thus particularly useful for unraveling the role of Tax immortalization activity during leukemogenesis independently of viral replication. In this report, we describe the biological properties of BLV recombinant proviruses mutated in the Tax phosphorylation sites (BLVTax106+293). Titration of the proviral loads by semiquantitative PCR revealed that the BLV mutants propagated at wild-type levels in vivo. Furthermore, two animals (sheep 480 and 296) infected with BLVTax106+293 developed leukemia or lymphosarcoma after 16 and 36 months, respectively. These periods of time are within the normal range of latencies preceding the onset of pathogenesis induced by wild-type viruses. The phenotype of the mutant-infected cells was characteristic of a B lymphocyte (immunoglobulin M positive) expressing CD11b and CD5 (except at the final stage for the latter marker), a pattern that is typical of wild-type virus-infected target cells. Interestingly, the transformed B lymphocytes from sheep 480 also coexpressed the CD8 marker, a phenotype rarely observed in tumor biopsies from chronic lymphocytic leukemia patients. Finally, direct sequencing of the tax gene demonstrated that the leukemic cells did not harbor revertant proviruses. We conclude that viruses expressing a Tax mutant unable to transform primary cells in culture are still pathogenic in the sheep animal model. Our data thus provide a clear example of the discordant conclusions that can be drawn from in vitro immortalization assays and in vivo experiments. These observations could be of interest for other systems, such as the related human T-cell leukemia virus type 1, which currently lack animal models allowing the study of the leukemogenic process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11024116      PMCID: PMC102026          DOI: 10.1128/jvi.74.21.9895-9902.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  81 in total

1.  Emergence of double-positive CD4/CD8 cells from adult peripheral blood mononuclear cells infected with human T cell leukemia virus type I (HTLV-I).

Authors:  B Macchi; G Graziani; J Zhang; A Mastino
Journal:  Cell Immunol       Date:  1993-07       Impact factor: 4.868

2.  In vivo leukocyte tropism of bovine leukemia virus in sheep and cattle.

Authors:  I Schwartz; A Bensaid; B Polack; B Perrin; M Berthelemy; D Levy
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

3.  Large granular lymphocytosis in a patient infected with HTLV-II.

Authors:  M P Martin; R J Biggar; G Hamlin-Green; S Staal; D Mann
Journal:  AIDS Res Hum Retroviruses       Date:  1993-08       Impact factor: 2.205

4.  Human T lymphotropic virus type II (HTLV-II) infection among female prostitutes in Yucatan, Mexico.

Authors:  R A Gongora-Biachi; P Gonzalez-Martinez; C Castros-Sansores; N Pavia-Ruz; D L Rudolph; R B Lal
Journal:  Am J Med Sci       Date:  1993-10       Impact factor: 2.378

5.  The Sukhumi primate monkey model for viral lymphomogenesis: high incidence of lymphomas with presence of STLV-I and EBV-like virus.

Authors:  H Schätzl; M Tschikobava; D Rose; A Voevodin; H Nitschko; E Sieger; U Busch; K von der Helm; B Lapin
Journal:  Leukemia       Date:  1993-08       Impact factor: 11.528

6.  Involvement of the cyclic AMP-responsive element binding protein in bovine leukemia virus expression in vivo.

Authors:  E Adam; P Kerkhofs; M Mammerickx; R Kettmann; A Burny; L Droogmans; L Willems
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

7.  CD8-positive B-cell chronic lymphocytic leukemia. A report of two cases.

Authors:  D D Koelliker; P E Steele; P E Hurtubise; H C Flessa; Y P Sheng; S H Swerdlow
Journal:  Am J Clin Pathol       Date:  1994-08       Impact factor: 2.493

8.  In vivo infection of sheep by bovine leukemia virus mutants.

Authors:  L Willems; R Kettmann; F Dequiedt; D Portetelle; V Vonèche; I Cornil; P Kerkhofs; A Burny; M Mammerickx
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Bovine leukemia virus induces CD5- B cell lymphoma in sheep despite temporarily increasing CD5+ B cells in asymptomatic stage.

Authors:  K Murakami; K Okada; Y Ikawa; Y Aida
Journal:  Virology       Date:  1994-07       Impact factor: 3.616

10.  Immunopathologic study and characterization of the phenotype of transformed cells in sheep with bovine leukemia virus-induced lymphosarcoma.

Authors:  K Murakami; Y Aida; R Kageyama; S Numakunai; K Ohshima; K Okada; Y Ikawa
Journal:  Am J Vet Res       Date:  1994-01       Impact factor: 1.156

View more
  8 in total

1.  Increased cell proliferation, but not reduced cell death, induces lymphocytosis in bovine leukemia virus-infected sheep.

Authors:  Christophe Debacq; Becca Asquith; Pierre Kerkhofs; Daniel Portetelle; Arsène Burny; Richard Kettmann; Luc Willems
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

2.  Even attenuated bovine leukemia virus proviruses can be pathogenic in sheep.

Authors:  Arnaud Florins; Nicolas Gillet; Mathieu Boxus; Pierre Kerkhofs; Richard Kettmann; Luc Willems
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

3.  A mutant form of the tax protein of bovine leukemia virus (BLV), with enhanced transactivation activity, increases expression and propagation of BLV in vitro but not in vivo.

Authors:  Shigeru Tajima; Masahiko Takahashi; Shin-Nosuke Takeshima; Satoru Konnai; Shan Ai Yin; Shinobu Watarai; Yoshimasa Tanaka; Misao Onuma; Kosuke Okada; Yoko Aida
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  Involvement of glutathione as a mechanism of indirect protection against spontaneous ex vivo apoptosis associated with bovine leukemia virus.

Authors:  Teresa Sanchez Alcaraz; Pierre Kerkhofs; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 5.  BLV: lessons on vaccine development.

Authors:  Alejandro Abdala; Irene Alvarez; Hélène Brossel; Luis Calvinho; Hugo Carignano; Lautaro Franco; Hélène Gazon; Christelle Gillissen; Malik Hamaidia; Clotilde Hoyos; Jean-Rock Jacques; Thomas Joris; Florent Laval; Marcos Petersen; Florent Porquet; Natalia Porta; Vanesa Ruiz; Roghaiyeh Safari; Guillermo Suárez Archilla; Karina Trono; Luc Willems
Journal:  Retrovirology       Date:  2019-10-07       Impact factor: 4.602

6.  A dose-effect relationship for deltaretrovirus-dependent leukemogenesis in sheep.

Authors:  Carole Pomier; Maria Teresa Sanchez Alcaraz; Christophe Debacq; Agnes Lançon; Pierre Kerkhofs; Lucas Willems; Eric Wattel; Franck Mortreux
Journal:  Retrovirology       Date:  2009-04-03       Impact factor: 4.602

Review 7.  Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Authors:  Nicolas Gillet; Arnaud Florins; Mathieu Boxus; Catherine Burteau; Annamaria Nigro; Fabian Vandermeers; Hervé Balon; Amel-Baya Bouzar; Julien Defoiche; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2007-03-16       Impact factor: 4.602

8.  Comparison of bovine leukemia virus (BLV) and CMV promoter-driven reporter gene expression in BLV-infected and non-infected cells.

Authors:  Jerome S Harms; Kurt A Eakle; Lillian S Kuo; Robert D Bremel; Gary A Splitter
Journal:  Genet Vaccines Ther       Date:  2004-08-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.